Program Description
Shire would like to personally invite you to a presentation on CUVITRU™ [Immune Globulin Subcutaneous (Human)], 20% Solution. This live session will provide a unique opportunity to interact with your peers and our guest speaker in a facilitated discussion about the distinct needs and treatment of patients with primary humoral immunodeficiency.

Program Objectives
- Discuss CUVITRU [Immune Globulin Subcutaneous (Human)], 20% Solution, a treatment option for adult and pediatric patients 2 years of age and older with primary immunodeficiency (PI)
- Discuss PI patient types that might be good candidates to consider for treatment with CUVITRU

Agenda
- 06:00pm [Arrivals and Registration]
- 06:30pm Presentation
- 07:30pm [Q&A Session]
- 8:00pm [Closing Remarks]

Location
The Hotel Hershey
100 Hotel Rd.
Hershey, PA 17033

Speaker
Anthony Rooklin MD.
Clinical Associate Professor of Pediatrics, Thomas Jefferson University Philadelphia, PA

Friday, June 23rd, 2017
Please contact your Shire Territory Business Manager, Katie White Austin, at katie.white.austin@shire.com if you would like to attend this program.

To RSVP to attend this program, register at the website below
https://Shire.cvent.com/062317PA

Please see the back page for Indication and Important Safety Information, and the accompanying Full Prescribing Information including Boxed Warning regarding Thrombosis.

This is a non-CME event sponsored by Shire. In accordance with state laws, we are prohibited from providing meals and food items to healthcare professionals licensed or practicing in the states of Minnesota and Vermont. Invited participants may not bring guests. Shire will collect and report healthcare professional information concerning meals and other transfers of value pursuant to the Federal Sunshine Act and state laws.
CUVITRU Indication and Important Safety Information

Indication
CUVITRU is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Solution indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older.

CUVITRU is for subcutaneous infusion only.

Important Safety Information

BOXED WARNING: THROMBOSIS
Thrombosis may occur with immune globulin products, including CUVITRU. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors.

For patients at risk of thrombosis, administer CUVITRU at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

CONTRAINDICATIONS
CUVITRU is contraindicated in patients who have had an anaphylactic or severe systemic hypersensitivity reaction to the subcutaneous administration of human immune globulin and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity to human immune globulin treatment.

WARNINGS and PRECAUTIONS
Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human immune globulin. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Renal Dysfunction/Failure: Monitor renal function and urine output and consider lower, more frequent dosing in patients who are at risk of developing renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure.

Thrombosis: Monitor for signs and symptoms of thrombosis and assess blood viscosity for those at risk for hyperviscosity.

Aseptic Meningitis Syndrome (AMS): Monitor for clinical signs and symptoms of AMS.

Hemolysis: Monitor for clinical signs and symptoms of hemolysis and delayed hemolytic anemia.

Transfusion-Related Acute Lung Injury (TRALI): Monitor for pulmonary adverse reactions associated with TRALI.

Transmittable Infectious Agents: Because CUVITRU is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses and other pathogens. No confirmed cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with CUVITRU.

Interference with Laboratory Tests: False positive serological test results, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

ADVERSE REACTIONS
The most common adverse reactions observed in clinical trials in ≥ 5% of patients were: local adverse reactions, systemic adverse reactions including headache, nausea, fatigue, diarrhea, and vomiting.

Please see the accompanying Full Prescribing Information, including Boxed Warning regarding Thrombosis.